Search
Hydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[A192132] **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020. … [L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546]
Synonyms: 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline, 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinolineProducts: PMS-hydroxychloroquineNiacin
go.drugbank.com/drugs/DB00627ApprovedInvestigationalNutraceuticalNiacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
Mixtures: Vege Swiss One Multivitamin W Chel Mins Tab, Pro Enz TabProducts: Niaspan ERLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding[A37050
Categories: Drugs Used in DiabetesProducts: LINAGLIPTIN EGCarboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigational[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248] … Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.
Categories: Compounds used in a research, industrial, or household settingProducts: PLATINWAS 150 MG 10MG/ML ENJ. FLAKON, 1 ADET, PLATINWAS 450 MG 10MG/ML ENJ. FLAKON, 1 ADETBaclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigational[A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977. … Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients.
Products: PMS-baclofen, PMS-BACLOFEN TABLET 10 mgLosartan
go.drugbank.com/drugs/DB00678ApprovedInvestigational[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423] … [L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.
Synonyms: 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazoleMixtures: PMS-losartan-hctz, PMS-losartan-hctzSennosides
go.drugbank.com/drugs/DB11365ApprovedInvestigationalSennoside A, one of the sennosides present in the laxative medication, has recently proven effective in inhibiting the ribonuclease H (RNase H) activity of human immunodeficiency virus (HIV) reverse transcriptase … Sennosides (also known as senna glycoside or senna) is a medication used to treat constipation[FDA Label][L771] and empty the large intestine before surgery.
Mixtures: EX-lax Gentle Strength, Laxatif De Sene Et Docusate De SodiumProducts: Senna Gen, EX-lax Maximum Strength Stimulant LaxativeFlurbiprofen
go.drugbank.com/drugs/DB00712ApprovedInvestigationalFlurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, os...
Products: STREPSILS INTENSIVE SOLUCION EN SPRAY SABOR A MIEL Y LIMON, FLURBIPROFENE EG LABORATORI EUROGENERICIIpratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational] was approved in 1996. … Ipratropium is a quaternary ammonium derivative of [atropine][A176957] that acts as an anticholinergic agent.
Mixtures: SALBUTAMOLO E IPRATROPIO BROMURO EG, BERODUAL N METERED DOSE INHALERProducts: PMS-ipratropium, ATROVENT N METERED DOSE INHALER 20 mcg/puffLetrozole
go.drugbank.com/drugs/DB01006ApprovedInvestigational[A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623] … Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.
Products: PMS-letrozole, LETROZOLO EG